" class="no-js "lang="en-US"> ViroCell Biologics - Medtech Alert
Friday, August 01, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
ViroCell Biologics | Pharmtech Focus

ViroCell Biologics

About ViroCell Biologics

ViroCell Biologics

ViroCell Biologics is an innovation-driven Contract Development and Manufacturing Organization (CDMO) that manufactures viral vectors and gene-modified cells to enable novel cell and gene therapies to enter clinical trials.

Related Story

Appointments

 ViroCell Strengthens Senior Management Team with Appointment of Nick Maishman as COO | PTF

ViroCell Strengthens Senior Management Team with Appointment of Nick Maishman as COO

November 22 2022

ViroCell Biologics, founded by the UK’s most prolific academic viral vector manufacturing team, today announces […]

Appointments

 ViroCell Announces the Appointment of Susan B. Nichols as CBO | Pharmtech Focus

ViroCell Announces the Appointment of Susan B. Nichols as CBO

September 20 2022

ViroCell, an innovation-driven Contract Development and Manufacturing Organization (“CDMO”), is addressing the global viral vector supply […]

Industry News

 ViroCell Biologics and Great Ormond Street Hospital for Children Announce Partnership to Dislodge Gene and Cell Therapy “Logjam” | Pharmtech Focus

ViroCell Biologics and Great Ormond Street Hospital for Children Announce Partnership to Dislodge Gene and Cell Therapy “Logjam”

September 28 2021

ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, and […]

Appointments

 ViroCell Announces New Board Appointments | Pharmtech Focus

ViroCell Announces New Board Appointments

August 17 2021

ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, today […]